Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents

Abstract

Abstract Objectives To explore in the daily clinical practice setting that antimuscarinic, fesoterodine or solifenacin, provides a greater clinical benefit after changing the prior overactive bladder (OAB) therapy with tolterodine extended release (ER) to other novel antimuscarinic agents. Material and methods A post hoc analysis of data from an observational multicenter, cross-sectional, retrospective study. Adult patients of both sexes, with OAB and OAB-V8 score ≥ 8, who switched to fesoterodine or solifenacin within the 3–4 months before study visit from their prior tolterodine-ER-based therapy due to poor response were included. 92 patients were selected for each treatment group, matched (1:1) according to conditioned probability using the propensity score. Benefit of treatment change perceived by the physician and patient was evaluated by means of the Clinical Global Impression of Improvement subscale (CGI-I) and Treatment Benefit Scale (TBS), respectively. Degree of worry, bother and interference with daily living activities due to urinary symptoms, level of satisfaction, and preference for current treatment were also assessed. Results Fesoterodine provided a significantly greater improvement than solifenacin in terms of therapeutic benefit perceived by the physician according to ICG-I. 96.7% of the patients on fesoterodine treatment vs. 81.6% of the solifenacin group showed a score of improvement in TBS (p Conclusions In daily clinical practice the switch from tolterodine LP to fesoterodine seems to provide greater benefits both from the physician's and the patient's point of view compared with those provided by solifenacin.